NEW YORK, Jan. 30, 2006 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including the KRX-101 (sulodexide) Phase II data and the ongoing Phase III/IV clinical program, at The Brean Murray, Carret Small Cap Institutional Investor Conference in New York City. Mr. Weiss' presentation will take place on Wednesday, February 1, 2006, at 10:00 a.m. Eastern Time at the Grand Hyatt New York Hotel. A live audio webcast of Mr. Weiss' presentation will be available at http://www.wsw.com/webcast/bmry2/kerx/. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.